Adalimumab and Infliximab Are Equally Effective for Crohn's Disease in Patients Not Previously Treated With Anti-Tumor Necrosis Factor-alpha Agents

C. Kestens, M.G.H. van Oijen, C.L.J. Mulder, A.A. van Bodegraven, G. Dijkstra, D. de Jong, C. Ponsioen, B.A.C. van Tuyl, P.D. Siersema, H.H. Fidder, B. Oldenburg

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)826-831
JournalClinical Gastroenterology and Hepatology
Issue number7
Publication statusPublished - 2013

Cite this